BACKGROUND: Ovarian clear cell carcinoma (OCCC) is resistant to platinum chemotherapy and is characterized by poor prognosis. Today, the use of poly (ADP-ribose) polymerase (PARP) inhibitor, which is based on synthetic lethality strategy and characterized by cancer selectivity, is widely used for new types of molecular-targeted treatment of relapsed platinum-sensitive ovarian cancer. However, it is less effective against OCCC. METHODS: We conducted siRNA screening to identify synthetic lethal candidates for the ARID1A mutation; as a result, we identified Cyclin-E1 (CCNE1) as a potential target that affects cell viability. To further clarify the effects of CCNE1, human OCCC cell lines, namely TOV-21G and KOC7c (ARID1A mutant lines), and RMG-I and ES2 (ARID1A wild type lines) were transfected with siRNA targeting CCNE1 or a control vector. RESULTS: Loss of CCNE1 reduced proliferation of the TOV-21G and KOC7c cells but not of the RMG-I and ES2 cells. Furthermore, in vivo interference of CCNE1 effectively inhibited tumor cell proliferation in a xenograft mouse model. CONCLUSION: This study showed for the first time that CCNE1 is a synthetic lethal target gene to ARID1A-mutated OCCC. Targeting this gene may represent a putative, novel, anticancer strategy in OCCC treatment.
BACKGROUND:Ovarian clear cell carcinoma (OCCC) is resistant to platinum chemotherapy and is characterized by poor prognosis. Today, the use of poly (ADP-ribose) polymerase (PARP) inhibitor, which is based on synthetic lethality strategy and characterized by cancer selectivity, is widely used for new types of molecular-targeted treatment of relapsed platinum-sensitive ovarian cancer. However, it is less effective against OCCC. METHODS: We conducted siRNA screening to identify synthetic lethal candidates for the ARID1A mutation; as a result, we identified Cyclin-E1 (CCNE1) as a potential target that affects cell viability. To further clarify the effects of CCNE1, human OCCC cell lines, namely TOV-21G and KOC7c (ARID1A mutant lines), and RMG-I and ES2 (ARID1A wild type lines) were transfected with siRNA targeting CCNE1 or a control vector. RESULTS: Loss of CCNE1 reduced proliferation of the TOV-21G and KOC7c cells but not of the RMG-I and ES2 cells. Furthermore, in vivo interference of CCNE1 effectively inhibited tumor cell proliferation in a xenograft mouse model. CONCLUSION: This study showed for the first time that CCNE1 is a synthetic lethal target gene to ARID1A-mutated OCCC. Targeting this gene may represent a putative, novel, anticancer strategy in OCCC treatment.
Authors: Helen J Mackay; Mark F Brady; Amit M Oza; Alexander Reuss; Eric Pujade-Lauraine; Ann M Swart; Nadeem Siddiqui; Nicoletta Colombo; Michael A Bookman; Jacobus Pfisterer; Andreas du Bois Journal: Int J Gynecol Cancer Date: 2010-08 Impact factor: 3.437
Authors: Raymond P Perez; Lionel D Lewis; Andrew P Beelen; Anthony J Olszanski; Nicholas Johnston; C Harker Rhodes; Bernard Beaulieu; Marc S Ernstoff; Alan Eastman Journal: Clin Cancer Res Date: 2006-12-01 Impact factor: 12.531
Authors: Kimberly C Wiegand; Sohrab P Shah; Osama M Al-Agha; Yongjun Zhao; Kane Tse; Thomas Zeng; Janine Senz; Melissa K McConechy; Michael S Anglesio; Steve E Kalloger; Winnie Yang; Alireza Heravi-Moussavi; Ryan Giuliany; Christine Chow; John Fee; Abdalnasser Zayed; Leah Prentice; Nataliya Melnyk; Gulisa Turashvili; Allen D Delaney; Jason Madore; Stephen Yip; Andrew W McPherson; Gavin Ha; Lynda Bell; Sian Fereday; Angela Tam; Laura Galletta; Patricia N Tonin; Diane Provencher; Dianne Miller; Steven J M Jones; Richard A Moore; Gregg B Morin; Arusha Oloumi; Niki Boyd; Samuel A Aparicio; Ie-Ming Shih; Anne-Marie Mes-Masson; David D Bowtell; Martin Hirst; Blake Gilks; Marco A Marra; David G Huntsman Journal: N Engl J Med Date: 2010-09-08 Impact factor: 91.245
Authors: Rowan E Miller; Rachel Brough; Ilirjana Bajrami; Chris T Williamson; Simon McDade; James Campbell; Asha Kigozi; Rumana Rafiq; Helen Pemberton; Rachel Natrajan; Josephine Joel; Holly Astley; Claire Mahoney; Jonathan D Moore; Chris Torrance; John D Gordan; James T Webber; Rebecca S Levin; Kevan M Shokat; Sourav Bandyopadhyay; Christopher J Lord; Alan Ashworth Journal: Mol Cancer Ther Date: 2016-06-30 Impact factor: 6.261
Authors: Joseph J Caumanns; Katrien Berns; G Bea A Wisman; Rudolf S N Fehrmann; Tushar Tomar; Harry Klip; Gert J Meersma; E Marielle Hijmans; Annemiek M C Gennissen; Evelien W Duiker; Desiree Weening; Hiroaki Itamochi; Roelof J C Kluin; Anna K L Reyners; Michael J Birrer; Helga B Salvesen; Ignace Vergote; Els van Nieuwenhuysen; James Brenton; E Ioana Braicu; Jolanta Kupryjanczyk; Beata Spiewankiewicz; Lorenza Mittempergher; René Bernards; Ate G J van der Zee; Steven de Jong Journal: Clin Cancer Res Date: 2018-04-23 Impact factor: 12.531
Authors: Hannah Farmer; Nuala McCabe; Christopher J Lord; Andrew N J Tutt; Damian A Johnson; Tobias B Richardson; Manuela Santarosa; Krystyna J Dillon; Ian Hickson; Charlotte Knights; Niall M B Martin; Stephen P Jackson; Graeme C M Smith; Alan Ashworth Journal: Nature Date: 2005-04-14 Impact factor: 69.504